Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 711 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 
Table of Contents
LETTER TO THE EDITOR
Year : 2012  |  Volume : 16  |  Issue : 3  |  Page : 474-475

Injection site lipodystrophy and the endocrinologist


Department of Endocrinology, Army Hospital (Research and Referral), Delhi Cantonment, India

Date of Web Publication5-May-2012

Correspondence Address:
M K Garg
Department of Endocrinology, Army Hospital (Research and Referral), Delhi Cantonment - 110010
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2230-8210.95729

Rights and Permissions

How to cite this article:
Gundgurthi A, Dutta MK, Pakhetra R, Garg M K. Injection site lipodystrophy and the endocrinologist. Indian J Endocr Metab 2012;16:474-5

How to cite this URL:
Gundgurthi A, Dutta MK, Pakhetra R, Garg M K. Injection site lipodystrophy and the endocrinologist. Indian J Endocr Metab [serial online] 2012 [cited 2019 Aug 24];16:474-5. Available from: http://www.ijem.in/text.asp?2012/16/3/474/95729

Sir,

A 7-year-old boy diagnosed to have Dandy-Walker syndrome was referred for evaluation of short stature. He had previously undergone ventriculo-peritoneal shunting at 2 years of age. His growth velocity in the preceding year was 2 cm. His height was 95 cm (height age 4 years, height SDS −2.19, target paternal height 163 cm), weight was 15 kg (weight age 5 years, weight SDS −1.0), bone age was 4.6 years, and head circumference was 60 cm. Hematological and biochemical parameters were normal. Free triiodothyronine was 2.2 (2.4-4.2) pg/mL, free thyroxine was 0.55 (0.8-2.1) ng/mL, and thyroid stimulating hormone was 0.09 (0.5-6.5) μU/mL, suggestive of secondary hypothyroidism. Stimulated cortisol (post ACTH) was 20.3 μg/dL. He was started on thyroxine replacement. Once euthyroidism was achieved, growth hormone (GH) stimulation tests were performed. Insulin tolerance test and clonidine stimulation test revealed GH levels of 2.1 ng/mL and 3.3 ng/mL, respectively. He was initiated on GH therapy. The child and the parents were educated about the injection technique. At periodic review at 9 months after GH was started, examination of abdomen revealed cutaneous hypertrophy on the abdomen on either side of the umbilicus [Figure 1]a. On enquiring about the injection technique, parents reported that they injected GH at fixed places. They were counseled to avoid injecting in these areas and follow rotation technique. The boy was reviewed at 6 months subsequently and lipohypertrophy had subsided [Figure 1]b. He has gained 12 cm after being initiated on GH.
Figure 1: (a) Injection site hypertrophy seen in the encircled area. (b) Resolution of hypertrophy avoiding the site for GH injections. Also seen is the scar mark of ventriculo-peritoneal shunt

Click here to view


The list of drugs causing localized lipodystrophy is widening. Insulin is well known to cause lipodystrophy - either hypertrophy (due to anabolic actions) or atrophy (local immune reaction to crystals of impure insulin). GH inhibits adipocyte differentiation, reduces triglyceride accumulation, and increases lipolysis which reduces adipose tissue mass. [1] It would be logical to expect lipoatrophy with prolonged GH injection as evidenced by clinical studies using daily GH or once weekly peglylated GH preparation. [2] However, lipohypertrophy described in the case above represents a paradox which has been infrequently reported previously. [3],[4] Cells are capable of synthesizing insulin like growth factor 1 (IGF-1). IGF-1 can act in autocrine/paracrine manner to induce adipocyte hypertrophy acting through IGF-1 receptors present on adipocyte. IGF-1 is also known to be a potent regulator of pre-adipocyte proliferation. [5] With these evidences, one can postulate that chronic stimulation of subcutaneous adipocytes by GH injected might increase the local production of IGF-1 which would result in lipohypertrophy as seen in our patient. And the absence of this stimulus resulted in regression of lipohypertrophy.

Other injectable drugs concerned with endocrinology as they are known to cause lipodystrophy are corticosteroids (atrophy), octreotide (atrophy), pegvisomant (hypertrophy), and IGF-1 (hypertrophy).

This case should alert the clinician regarding lipodystrophy, which can hamper optimal drug absorption, occurring with commonly used injectable medications. The injection site should be periodically examined and the patient should be counseled about the rotation technique of injection.

 
   References Top

1.Richelsen B. Action of growth hormone in adipose tissue. Horm Res 1997;48 Suppl 5:105-10.  Back to cited text no. 1
[PUBMED]    
2.Touraine P, D'Souza GA, Kourides I, Abs R, Barclay P, Xie R, et al. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. Eur J Endocrinol 2009;161:533-40.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  
3.Ruvalcaba RH, Klutter KB. Abdominal lipohypertrophy caused by injections of growth hormone: A case report. Pediatrics 1998;102:408-10.  Back to cited text no. 3
    
4.Mersebach H, Feldt-Rasmussen UF. Localized hypertrophy during growth hormone therapy. Ugeskr Laeger 2002;164:1930-2.  Back to cited text no. 4
[PUBMED]    
5.Holly J, Sabin M, Perks C, Shield J. Adipogenesis and IGF-1. Metab Syndr Relat Disord 2006;4:43-50.  Back to cited text no. 5
[PUBMED]    


    Figures

  [Figure 1]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References
    Article Figures

 Article Access Statistics
    Viewed1263    
    Printed26    
    Emailed0    
    PDF Downloaded215    
    Comments [Add]    

Recommend this journal